Oncologyanalytics.com

Your abstract submission has been received
Click to print this page now.
You have submitted the following abstract to 2013 ASCO Annual Meeting (May 31 - June 4, 2013). Receipt of
this notice does not guarantee that your submission was complete, free of errors, or accepted for
presentation. Abstract notifications will be sent to the first author by early March.
Off-label capecitabine, eribulin, or ixabepilone use in metastatic breast cancer (MBC). Laura Rose Bobolts, Akhil Kumar, Marc L. Fishman, William S. Shimp, James Edward Krook, Val Fishman, Sharon Davis, Carol Anthony, Robert Walton, Dinah Huff, William John Michael Hrushesky; Oncology Analytics, Plantation, FL; Oncology Analytics, Inc., Plantation, FL Abstract Text: Background: Anthracyclines and taxanes have proven to be the most effective
treatments for MBC. The FDA indications for capecitabine, eribulin, and ixabepilone
recommend prior anthracycline and taxane therapy, unless contraindicated. The
proportion of patients who receive these drugs after having received an anthracycline
and/or taxane is unknown. We retrospectively reviewed capecitabine, eribulin, and
ixabepilone treatment requests to examine the utilization patterns, specifically in relation
to prior anthracycline and/or taxane therapy. Methods: All capecitabine, eribulin, or
ixabepilone requests for MBC from 2009 through January 2013 were reviewed. The
proportion of requests for these agents with and without FDA stipulated prior therapies
were contrasted, using Chi squared analyses. Results: 36 MBC requests were
identified for capecitabine, eribulin, or ixabepilone. The majority (67%) of these occurred
among patients who had no documentation of prior anthracycline therapy. 36% of all
requests were not preceded by any documented taxane therapy. Anthracyclines were
avoided more frequently than taxanes (P=0.011). All requests without documentation of
prior taxane use (36%; 13/36) were also made without prior anthracycline use.
Oncologists were more likely to initiate capecitabine without prior anthracycline and
taxane, as compared to eribulin or ixabepilone (64% v 18% v 18%, respectively;
P=0.042).
Conclusions: In our sample, more than two thirds of MBC treatment requests for
eribulin, capecitabine, or ixabepilone occurred prior to a request for an anthracycline,
and more than a third prior to receiving a taxane. Since, in general, it is considered
standard of care to use the most active drugs early in the course of disease, this trend
could have negative effects upon the optimal control of MBC.
Title:
Off-label capecitabine, eribulin, or ixabepilone use in metastatic breast cancer (MBC).
Submitter's E-mail Address:
[email protected]
Is this a late-breaking abstract?
No
Is this abstract a clinical trial?
No
Would like to be considered for a Merit Award:
No
Trial Type:
N/A
Research Category:
N/A
Continued Trial Accrual:
No
Recieved Grant funding:
No
All participants where over the age of 65:
No
Sponsor: William S. Shimp, MD
First Author
Presenting Author
Laura Rose Bobolts, BCOP, PharmD
Oncology Analytics
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Second Author
Akhil Kumar, MD
Oncology Analytics, Inc.
8751 W. Broward Boulevard
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Third Author
Marc L. Fishman, MD
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Fourth Author
William S. Shimp, MD
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Fifth Author
James Edward Krook, MD
Oncology Analytics
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Phone Number: 218-786-3625
Email: [email protected]
Click to view Conflict of Interest Disclosure
Sixth Author
Val Fishman, RN
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Seventh Author
Sharon Davis, MPH
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Eighth Author
Carol Anthony, MT BB (ASCP)
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Ninth Author
Robert Walton, MS
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Tenth Author
Dinah Huff, MD
Oncology Analytics, Inc.
8751 W Broward Blvd
Suite # 500
Plantation, FL 33324
Email: [email protected]
Click to view Conflict of Interest Disclosure
Eleventh Author
William John Michael Hrushesky, MD
Oncology Analytics
Plantation, FL
Email: [email protected]
Click to view Conflict of Interest Disclosure

Source: http://www.oncologyanalytics.com/publications/2013_ASCO_Abstract-5_off-label_xeloda_ixempra_eribulin_in_MBC.pdf